Literature DB >> 32960471

Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.

Hui Xu1, Maosheng Lin2,3, Yingying Hu2,4, Li Zhang2,3, Qiaoqiao Li2,3, Jinhan Zhu2,3, Shi Wang5, Mian Xi2,3.   

Abstract

BACKGROUND: The objective of this study was to investigate the relationship between clinical characteristics, as well as dosimetric parameters, and the risk of treatment-related lymphopenia in esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT).
MATERIALS AND METHODS: Clinical characteristics and dosimetric parameters were collected from 436 patients with ESCC who received definitive CRT from 2010 through 2017. Absolute lymphocyte counts (ALCs) were obtained before, during, and 1 month after CRT. Grade 4 (G4) lymphopenia was defined as ALC <0.2 × 109 /L during CRT. Logistic regression analysis was used to evaluate the effect of each factor on predicting G4 lymphopenia. The relationship between lymphopenia and overall survival (OS) was examined, and a nomogram was developed to predict OS.
RESULTS: G4 lymphopenia was observed in 103 patients (23.6%) during CRT. Multivariate analysis indicated that planning target volume (PTV), lung V10 , heart V10 , performance status, and pretreatment lymphopenia were significant risk factors for G4 lymphopenia. Patients with G4 lymphopenia had significantly worse survival than those without. Based on multivariate analysis, clinical TNM stage, radiotherapy modality, pretreatment ALC, and G4 lymphopenia were predictive of OS and were incorporated into the nomogram, yielding a concordance index of 0.71.
CONCLUSIONS: G4 lymphopenia during definitive CRT was associated with larger PTVs, higher lung V10 and heart V10 , and worse survival. IMPLICATIONS FOR PRACTICE: The purpose of this study was to investigate the relationship between clinical characteristics, as well as dosimetric parameters, and the risk of treatment-related lymphopenia in 436 patients with esophageal squamous cell carcinoma who received definitive chemoradiotherapy. Grade 4 (G4) lymphopenia was observed in 23.6% of patients during radiotherapy. G4 lymphopenia was associated with larger planning target volumes, higher lung V10 and heart V10 , and worse survival. Then, a nomogram was built based on multivariate analysis, yielding excellent performance to predict overall survival. Prospective studies are needed to investigate potential approaches for mitigating severe lymphopenia, which may ultimately convert into survival benefits. © AlphaMed Press 2020.

Entities:  

Keywords:  Definitive chemoradiotherapy; Esophageal squamous cell carcinoma; Lymphopenia; Planning target volume; Prognosis

Year:  2020        PMID: 32960471      PMCID: PMC7930419          DOI: 10.1002/onco.13533

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  36 in total

1.  Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer.

Authors:  Mary Feng; Jean M Moran; Todd Koelling; Aamer Chughtai; June L Chan; Laura Freedman; James A Hayman; Reshma Jagsi; Shruti Jolly; Janice Larouere; Julie Soriano; Robin Marsh; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-24       Impact factor: 7.038

2.  The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.

Authors:  Wei Deng; Cai Xu; Amy Liu; Peter S N van Rossum; Weiye Deng; Zhongxing Liao; Albert C Koong; Radhe Mohan; Steven H Lin
Journal:  Radiother Oncol       Date:  2019-01-11       Impact factor: 6.280

3.  Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma.

Authors:  Hwa Kyung Byun; Nalee Kim; Sangjoon Park; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2019-04-15       Impact factor: 3.621

4.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Authors:  Kevin C Conlon; Enrico Lugli; Hugh C Welles; Steven A Rosenberg; Antonio Tito Fojo; John C Morris; Thomas A Fleisher; Sigrid P Dubois; Liyanage P Perera; Donn M Stewart; Carolyn K Goldman; Bonita R Bryant; Jean M Decker; Jing Chen; Tat'Yana A Worthy; William D Figg; Cody J Peer; Michael C Sneller; H Clifford Lane; Jason L Yovandich; Stephen P Creekmore; Mario Roederer; Thomas A Waldmann
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

5.  High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.

Authors:  Penny Fang; Wen Jiang; Rajayogesh Davuluri; Cai Xu; Sunil Krishnan; Radhe Mohan; Albert C Koong; Charles C Hsu; Steven H Lin
Journal:  Radiother Oncol       Date:  2018-03-09       Impact factor: 6.280

6.  Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

Authors:  Chad Tang; Zhongxing Liao; Daniel Gomez; Lawrence Levy; Yan Zhuang; Rediet A Gebremichael; David S Hong; Ritsuko Komaki; James W Welsh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

Review 7.  Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.

Authors:  Berend Jan van der Wilk; Ben M Eyck; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot
Journal:  Dig Surg       Date:  2018-09-18       Impact factor: 2.588

Review 8.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Authors:  Christine Ménétrier-Caux; Isabelle Ray-Coquard; Jean-Yves Blay; Christophe Caux
Journal:  J Immunother Cancer       Date:  2019-03-28       Impact factor: 13.751

9.  Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.

Authors:  Xi-Lei Zhou; Wei-Guo Zhu; Zhi-Jian Zhu; Wan-Wei Wang; Xue Deng; Wei-Jing Tao; Fu-Zhi Ji; Yu-Suo Tong
Journal:  Oncologist       Date:  2019-04-30

10.  A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer.

Authors:  David M Routman; Aurelie Garant; Scott C Lester; Courtney N Day; William S Harmsen; Cristobal T Sanheuza; Harry H Yoon; Michelle A Neben-Wittich; James A Martenson; Michael G Haddock; Christopher L Hallemeier; Kenneth W Merrell
Journal:  Adv Radiat Oncol       Date:  2019-01-17
View more
  5 in total

1.  Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach.

Authors:  Hao Yu; Fang Chen; Ka-On Lam; Li Yang; Yang Wang; Jian-Yue Jin; Aya Ei Helali; Feng-Ming Spring Kong
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

Review 2.  Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Dongjun Dai; Qiaoying Tian; Genhua Yu; Yongjie Shui; Hao Jiang; Qichun Wei
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 3.  Lymphopenia in Esophageal Cancer: What Have We Learned?

Authors:  Jia-Lin Wang; Rong Ma; Wei Kong; Ren Zhao; Yan-Yang Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

4.  Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis.

Authors:  Qi Zhao; Yanping Bi; Jiao Xue; Yandong Liu; Jiaxing Zhu; Songbing Qin
Journal:  Ann Transl Med       Date:  2022-07

5.  Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.

Authors:  Qian Wang; Qingtao Qiu; Zicheng Zhang; Jing Zhang; Guanghui Yang; Chengxin Liu; Baosheng Li
Journal:  Cancer Med       Date:  2021-08-07       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.